Biotech giant Genzyme will expand its Framingham campus with an $80-million processing facility that it says will “significantly” expand its purification capacity to support growth over the next few years, the Cambridge-based company announced today.
Genzyme said the investment will be for a new “downstream processing facility” for Fabrazyme, which treats a genetic disorder by helping to replace missing enzymes. It will be located adjacent to its current manufacturing site in Framingham.
“As we continue to meet the global demands for Fabrazyme and build inventory, our focus also remains on the future needs of the global Fabry community,” said Genzyme President and CEO, David Meeker. “Following last year’s regulatory approvals of our manufacturing facility in Framingham and a new vial filling line at our plant in Waterford, Ireland, we continue to execute on our global manufacturing strategy, enhancing our capabilities across the entire manufacturing process for Fabrazyme.”
Downstream processing involves the purification of material harvested from the cell culture manufacturing process, according to Genzyme.
(Image credit: freedigitalphotos.net)
Read more
Genzyme MS Drug Gets FDA Approval
Genzyme’s Growing Framingham Presence
Genzyme MS Treatment Approved In Europe
